Lixisenatide is effective and safe as add-on treatment to basal insulin in Asian individuals with type 2 diabetes and different body mass indices: a pooled analysis of data from the GetGoal Studies

• Xia Zhang,
• Ran Meng,
• Dalong Zhu,
• Weimin Wang,
• Guangyu Wu,
• Minlu Zhang,
• Wenhuan Feng,
• Huiqiu Yin

Affiliations

Xia Zhang

1 Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China

Ran Meng

3 Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

Dalong Zhu

5 Department of Endocrinology, Nanjing Medical University, Nanjing, China

Weimin Wang

National Center for Health Professions Education Development, Peking University, Beijing, China

Guangyu Wu

10 Qlife Lab Co., Ltd., Shanghai, China

Minlu Zhang

Serimmune, Goleta, California, USA

Wenhuan Feng

Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China

Huiqiu Yin

Department of Medical Affair, Sanofi, Shanghai, China